Tags

Type your tag names separated by a space and hit enter

Baicalein alleviates depression-like behavior in rotenone- induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway.
Biomed Pharmacother. 2021 Aug; 140:111556.BP

Abstract

BACKGROUND

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the world. In addition to motor symptoms, a variety of non-motor symptoms seriously affect the life quality of PD patients. Baicalein, a flavonoid extracted from the herb Scutellaria baicalensis Georgi, exhibits anti-PD activity through alleviation of its motor symptoms. However, its effects on non-motor symptoms were barely reported. This study aimed to investigate the therapeutic effects of baicalein on PD-related depression.

METHODS

After a 2-week injection of rotenone, mice with PD-related depression behavior were selected, divided into three groups, and administrated saline, baicalein, or madopar orally for four weeks. Behavior, neuroinflammation, neurotransmitters, and synaptic plasticity were evaluated.

RESULTS

Our results showed that 4-week baicalein treatment significantly alleviated the depression-like behavior in the rotenone-induced mice model. Repeated baicalein treatment reduced α-synuclein aggregation, inhibited neuroinflammation, and maintained neurotransmitters homeostasis. Moreover, we found that baicalein treatment could remarkably protect the synaptic plasticity and activate the BDNF/TrkB/CREB pathway in the PD-related depression mice model. As traditional dopamine replacement therapy unleashed few effects on depression-like symptom amelioration and synaptic function protection, baicalein might be a more appropriate choice for PD-related depression.

CONCLUSIONS

The current results suggested that baicalein could act as a treatment for PD-related depression.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Zhao X
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China.
Kong D
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China.
Zhou Q
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China.
Wei G
Guangdong Pharmaceutical University, Guangzhou 510006, China.
Song J
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China.
Liang Y
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China.
Du G
Beijing Key Laboratory of Drug Targets Research and New Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nongtan Street, Beijing, 100050, China. Electronic address: dugh@imm.ac.cn.

MeSH

AnimalsBrain-Derived Neurotrophic FactorCyclic AMP Response Element-Binding ProteinDepressionDisease Models, AnimalFlavanonesFlavonoidsHomeostasisInflammationMaleMembrane GlycoproteinsMiceMice, Inbred C57BLNeuronal PlasticityNeuroprotective AgentsNeurotransmitter AgentsParkinson DiseaseProtein-Tyrosine KinasesRotenoneSignal Transduction

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34087694

Citation

Zhao, Xiaoyue, et al. "Baicalein Alleviates Depression-like Behavior in Rotenone- Induced Parkinson's Disease Model in Mice Through Activating the BDNF/TrkB/CREB Pathway." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 140, 2021, p. 111556.
Zhao X, Kong D, Zhou Q, et al. Baicalein alleviates depression-like behavior in rotenone- induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed Pharmacother. 2021;140:111556.
Zhao, X., Kong, D., Zhou, Q., Wei, G., Song, J., Liang, Y., & Du, G. (2021). Baicalein alleviates depression-like behavior in rotenone- induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 140, 111556. https://doi.org/10.1016/j.biopha.2021.111556
Zhao X, et al. Baicalein Alleviates Depression-like Behavior in Rotenone- Induced Parkinson's Disease Model in Mice Through Activating the BDNF/TrkB/CREB Pathway. Biomed Pharmacother. 2021;140:111556. PubMed PMID: 34087694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baicalein alleviates depression-like behavior in rotenone- induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway. AU - Zhao,Xiaoyue, AU - Kong,Dewen, AU - Zhou,Qimeng, AU - Wei,Guangyi, AU - Song,Junke, AU - Liang,Yu, AU - Du,Guanhua, Y1 - 2021/06/01/ PY - 2021/01/14/received PY - 2021/03/23/revised PY - 2021/03/27/accepted PY - 2021/6/5/pubmed PY - 2021/7/30/medline PY - 2021/6/4/entrez KW - BDNF KW - Baicalein KW - Depression KW - Parkinson’s disease KW - Rotenone SP - 111556 EP - 111556 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed Pharmacother VL - 140 N2 - BACKGROUND: Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the world. In addition to motor symptoms, a variety of non-motor symptoms seriously affect the life quality of PD patients. Baicalein, a flavonoid extracted from the herb Scutellaria baicalensis Georgi, exhibits anti-PD activity through alleviation of its motor symptoms. However, its effects on non-motor symptoms were barely reported. This study aimed to investigate the therapeutic effects of baicalein on PD-related depression. METHODS: After a 2-week injection of rotenone, mice with PD-related depression behavior were selected, divided into three groups, and administrated saline, baicalein, or madopar orally for four weeks. Behavior, neuroinflammation, neurotransmitters, and synaptic plasticity were evaluated. RESULTS: Our results showed that 4-week baicalein treatment significantly alleviated the depression-like behavior in the rotenone-induced mice model. Repeated baicalein treatment reduced α-synuclein aggregation, inhibited neuroinflammation, and maintained neurotransmitters homeostasis. Moreover, we found that baicalein treatment could remarkably protect the synaptic plasticity and activate the BDNF/TrkB/CREB pathway in the PD-related depression mice model. As traditional dopamine replacement therapy unleashed few effects on depression-like symptom amelioration and synaptic function protection, baicalein might be a more appropriate choice for PD-related depression. CONCLUSIONS: The current results suggested that baicalein could act as a treatment for PD-related depression. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/34087694/Baicalein_alleviates_depression_like_behavior_in_rotenone__induced_Parkinson's_disease_model_in_mice_through_activating_the_BDNF/TrkB/CREB_pathway_ DB - PRIME DP - Unbound Medicine ER -